Tag Archives: CNAMTS

algorithms detecting deviant health care use in French Health Insurance databases

11 Nov

French health insurance for salaried executes algorithms on its databases with a public health purpose. The following published articles aim to target potential deviant behaviours or abuses that put at risk the health of the insured.

Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008.

Frauger E, Pauly V, Natali F, Pradel V, Reggio P, Coudert H, Thirion X, Micallef J.

CNS Drugs. 2011 May;25(5):415-24. doi: 10.2165/11587640-000000000-00000.

PMID:
21476612
Select item 206927782.

Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse.

Pauly V, Frauger E, Pradel V, Rouby F, Berbis J, Natali F, Reggio P, Coudert H, Micallef J, Thirion X.

Drug Alcohol Depend. 2011 Jan 1;113(1):29-36. doi: 10.1016/j.drugalcdep.2010.06.016. Epub 2010 Aug 8.

PMID:
20692778
Select item 198204053.

Estimation of clonazepam abuse liability: a new method using a reimbursed drug database.

Frauger E, Pauly V, Thirion X, Natali F, Pradel V, Reggio P, Rouby F, Coudert H, Micallef J.

Int Clin Psychopharmacol. 2009 Nov;24(6):318-24. doi: 10.1097/YIC.0b013e328330ae4b.

PMID:
19820405
10.

Assessment of abuse potential of benzodiazepines from a prescription database using ‘doctor shopping’ as an indicator.

Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M.

CNS Drugs. 2010 Jul;24(7):611-20. doi: 10.2165/11531570-000000000-00000.

PMID:
20527997

New blood thinners: the French studies in real life.

14 Jul

One more time CNAMTS boys have crunched the numbers from the reimbursement data bases.
They previously had done this exercise in real life for the mediator and they had found cardiac side effects. This time they investigated a new category of blood thinner the NACOs (Nouveaux Anti Coagulants). Unlike the mediator they have concluded that in the short term (3 months) no evidence of any adverse side effects such as bleeding or thrombosis could be found.

The mediator study:
http://www.ncbi.nlm.nih.gov/pubmed/20945504#

The NACOS study of the risk associated with the initiation of treatment with the new blood thinner in anticoagulant treatment naive patients (3 months of follow up):
http://ansm.sante.fr/var/ansm_site/storage/original/application/6372793e0dfaf927308665a647ed0444.pdf

The NACOS study of the risk associated with the change in treatment consisting in replacing Warfarin by the new blood thinner in anticoagulant treatment experienced patients (4 months of follow up):
http://ansm.sante.fr/var/ansm_site/storage/original/application/5504a80da7d6ec6eab26798eebf64fb3.pdf

%d bloggers like this: